Citius Pharma Inks Clinical Collaboration For I|ONTAK Combo Regime in Solid Tumor Settings
Citius Pharmaceuticals Inc (NASDAQ: CTXR ) collaborated with the University of Pittsburgh for I|ONTAK (denileukin diftitox or E7777) in combination with Merck Company, Inc. (NYSE: MRK ) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. The investigator-initiated trial at UPMC is an open-label, Phase 1|1b study consisting of two parts. Part I is a dose escalation study of four cohorts and … Full story available on Benzinga.com
Citius Pharma Inks Clinical Collaboration For I|ONTAK Combo Regime in Solid Tumor Settings
Citius Pharmaceuticals Inc (NASDAQ: CTXR ) collaborated with the University of Pittsburgh for I|ONTAK (denileukin diftitox or E7777) in combination with Merck Company, Inc. (NYSE: MRK ) Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. The investigator-initiated trial at UPMC is an open-label, Phase 1|1b study consisting of two parts. Part I is a dose escalation study of four cohorts and … Full story available on Benzinga.com